risperidone has been researched along with Aura in 17 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the atypical antipsychotic medications appear to be safe in patients with epilepsy, few studies have specifically addressed the use of risperidone in children with seizures." | 9.12 | Use of risperidone in children with epilepsy. ( Baccin, CE; Guerreiro, MM; Holzhausen, SP; Montenegro, MA, 2007) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 8.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 7.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 7.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "Although the atypical antipsychotic medications appear to be safe in patients with epilepsy, few studies have specifically addressed the use of risperidone in children with seizures." | 5.12 | Use of risperidone in children with epilepsy. ( Baccin, CE; Guerreiro, MM; Holzhausen, SP; Montenegro, MA, 2007) |
| "This retrospective study delineated the efficacy of antiepileptic drugs in preventing the need for methylphenidate in patients with benign childhood epilepsy with centrotemporal spikes and attention deficit hyperactivity disorder." | 4.88 | Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder? ( Fattal-Valevski, A; Goldberg-Stern, H; Kramer, U; Schneebaum-Sender, N, 2012) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 4.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "The aim of this paper was to explore the efficacy of modified electroconvulsive therapy (MECT) combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy, and the effects of insulin-like growth factor-1 mRNA and protein expression." | 3.83 | Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1. ( Li, C; Li, J, 2016) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 3.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| " They responded well to the reduction in dosage or to withdrawal of the apparent causing agent." | 2.49 | [Medication-related oculogyric crises: a description of four cases and a review of the literature]. ( Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013) |
| "Psychogenic non-epileptic seizures can co-exist with epileptic seizures." | 1.34 | Development of psychogenic non-epileptic seizures in response to auditory hallucinations. ( Devine, MJ; Duncan, JS, 2007) |
| "Oxcarbazepine (OZC) is a second-generation antiepileptic drug (AED) that also may be used as a mood stabilizer." | 1.33 | Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. ( Cacciola, M; D'Arrigo, C; La Torre, D; Migliardi, G; Pacetti, M; Rosaria Muscatello, M; Spina, E; Zoccali, R, 2005) |
| "The interictal "schizophrenia-like" psychoses of epilepsy conventionally are treated with antipsychotic medication with uncertain results." | 1.31 | Treatment of the interictal psychoses. ( Blumer, D; Montouris, G; Wakhlu, S; Wyler, AR, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Eaton, C | 1 |
| Yong, K | 1 |
| Walter, V | 1 |
| Mbizvo, GK | 1 |
| Rhodes, S | 1 |
| Chin, RF | 1 |
| Hosseini, H | 3 |
| Shafie, M | 3 |
| Shakiba, A | 3 |
| Ghayyem, H | 3 |
| Mayeli, M | 3 |
| Hassani, M | 3 |
| Aghamollaii, V | 3 |
| Citraro, R | 1 |
| Leo, A | 1 |
| Aiello, R | 1 |
| Pugliese, M | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Li, J | 1 |
| Li, C | 1 |
| Schneebaum-Sender, N | 1 |
| Goldberg-Stern, H | 1 |
| Fattal-Valevski, A | 1 |
| Kramer, U | 1 |
| Darling, A | 1 |
| Poo, P | 1 |
| Perez-Duenas, B | 1 |
| Campistol, J | 1 |
| Rapin, I | 1 |
| Gonzalez-Heydrich, J | 1 |
| Pandina, GJ | 1 |
| Fleisher, CA | 1 |
| Hsin, O | 1 |
| Raches, D | 1 |
| Bourgeois, BF | 1 |
| Biederman, J | 1 |
| Rosaria Muscatello, M | 1 |
| Pacetti, M | 1 |
| Cacciola, M | 1 |
| La Torre, D | 1 |
| Zoccali, R | 1 |
| D'Arrigo, C | 1 |
| Migliardi, G | 1 |
| Spina, E | 1 |
| Feroz-Nainar, C | 1 |
| Selvaraj, P | 1 |
| Roy, M | 1 |
| Ivanov, I | 1 |
| Klein, M | 1 |
| Green, WH | 1 |
| Coffey, B | 1 |
| Holzhausen, SP | 1 |
| Guerreiro, MM | 1 |
| Baccin, CE | 1 |
| Montenegro, MA | 1 |
| Devine, MJ | 1 |
| Duncan, JS | 1 |
| Mahgoub, NA | 1 |
| Terao, T | 1 |
| Kojima, H | 1 |
| Eto, A | 1 |
| Blumer, D | 1 |
| Wakhlu, S | 1 |
| Montouris, G | 1 |
| Wyler, AR | 1 |
| Bertoldo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy[NCT00323947] | Phase 4 | 33 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for risperidone and Aura
| Article | Year |
|---|---|
Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Central Nervous S | 2022 |
Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?
Topics: Age of Onset; Anticonvulsants; Attention; Attention Deficit Disorder with Hyperactivity; Central Ner | 2012 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Ch | 2013 |
1 trial available for risperidone and Aura
| Article | Year |
|---|---|
Use of risperidone in children with epilepsy.
Topics: Adolescent; Antipsychotic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Epileps | 2007 |
13 other studies available for risperidone and Aura
| Article | Year |
|---|---|
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epi | 2015 |
Study of modified electroconvulsive therapy combined with risperidone oral solution in the treatment of agitation in the acute stage of epilepsy and expression level changes of insulin-like growth factor-1.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Drug Combinations; Drug Therapy, Combination | 2016 |
The autistic-spectrum disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2002 |
No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; | 2004 |
Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Chromatography, High P | 2005 |
Risperidone induced oedema in a child with learning disability and autism.
Topics: Adolescent; Autistic Disorder; Dopamine Antagonists; Dose-Response Relationship, Drug; Edema; Epilep | 2006 |
The challenges of psychopharmacological management of children with severe developmental disabilities.
Topics: Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Caregivers; Child; Developmental Disabilit | 2006 |
Development of psychogenic non-epileptic seizures in response to auditory hallucinations.
Topics: Adult; Antipsychotic Agents; Epilepsy; Hallucinations; Humans; Male; Risperidone; Seizures | 2007 |
A report of successful treatment of psychosis in epilepsy with risperidone.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Epilepsy; Humans; Male; Psychotic Disorde | 2007 |
Risperidone and allergic reactions.
Topics: Aged; Drug Eruptions; Drug Hypersensitivity; Edema; Epilepsy; Humans; Male; Psychotic Disorders; Res | 1998 |
Treatment of the interictal psychoses.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Therapy, Combin | 2000 |
Valproic acid and risperidone.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Interactions; Epilepsy; Female; Humans; Psyc | 2002 |